Xbrane And Stada’s Ranibizumab Snapped Up In North America
Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada
Executive Summary
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.
You may also be interested in...
Xbrane Reveals Ranibizumab Refiling Plans For US
Xbrane has set out its plans to resubmit its application for a biosimilar rival to Lucentis in the US, after receiving details from the FDA on additional information needed for the agency to accept the BLA for review.
Xbrane Gets US Setback For Ranibizumab Filing
Xbrane Biopharma has withdrawn the BLA for its proposed Xlucane ranibizumab biosimilar rival to Lucentis in the US after the FDA said further information was required for it to accept the filing. Development partner Stada said it would “work closely” with Xbrane and US licensee Bausch + Lomb to get the product to market.
Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar
Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.